Novel genetic models of osteoporosis by overexpression of human RANKL in transgenic mice

Journal of Bone and Mineral Research

Volumn 29, Issue 5, 2014, Pages 1158-1169

  Rinotas, Vagelis ^a,b   Niti, Alexandra ^a   Dacquin, Romain ^c   Bonnet, Nicolas ^d   Stolina, Marina ^e   Han, Chun Ya ^e   Kostenuik, Paul ^e   Jurdic, Pierre ^c   Ferrari, Serge ^d   Douni, Eleni ^a,b  

^a AGRICULTURAL UNIVERSITY OF ATHENS   (Greece)

^b BIOMEDICAL SCIENCES RESEARCH CENTER ALEXANDER FLEMING   (Greece)

^c UNIVERSITÉ DE LYON   (France)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^e AMGEN INC   (United States)

Author keywords

animal models; bone; osteoporosis; RANKL; treatment

Indexed keywords

DENOSUMAB; OSTEOCLAST DIFFERENTIATION FACTOR; TNFSF11 PROTEIN, HUMAN;

ALBERS SCHOENBERG DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOMECHANICS; BONE REMODELING; BONE STRENGTH; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE; GENE DOSAGE; GENE OVEREXPRESSION; GENETIC MODEL; MALE; MOUSE; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; PHENOTYPE; POROSITY; PROTEIN ANALYSIS; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B GENE; SOFT TISSUE CALCIFICATION; TRABECULAR BONE; TRANSGENIC MOUSE; ANIMAL; BIOLOGICAL MODEL; BIOSYNTHESIS; CALCINOSIS; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; GROWTH PLATE; HUMAN; METABOLISM; OSTEOCLAST; PATHOLOGY;

ANIMALS; CALCINOSIS; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION; GROWTH PLATE; HUMANS; MICE; MICE, TRANSGENIC; MODELS, GENETIC; OSTEOCLASTS; OSTEOPETROSIS; OSTEOPOROSIS; RANK LIGAND;

EID: 84899053172     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2112     Document Type: Article

References (37)

1. Karsenty G, Wagner EF,. Reaching a genetic and molecular understanding of skeletal development. Dev Cell. 2002; 2 (4): 389-406.
2. Darby AJ,. Bone formation and resorption in postmenopausal osteoporosis. Lancet. 1981; 2 (8245): 536.
3. Fuller K, Wong B, Fox S, Choi Y, Chambers TJ,. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med. 1998; 188 (5): 997-1001.
4. Leibbrandt A, Penninger JM,. RANK/RANKL: regulators of immune responses and bone physiology. Ann NY Acad Sci. 2008; 1143: 123-50.
5. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998; 93 (2): 165-76.
6. Lacey DL, Tan HL, Lu J, et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol. 2000; 157 (2): 435-48.
7. Luan X, Lu Q, Jiang Y, et al. Crystal structure of human RANKL complexed with its decoy receptor osteoprotegerin. J Immunol. 2012; 189 (1): 245-52.
8. Kartsogiannis V, Zhou H, Horwood NJ, et al. Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues. Bone. 1999; 25 (5): 525-34.
9. O'Brien CA,. Control of RANKL gene expression. Bone. 2010; 46 (4): 911-9.
10. Hanada R, Hanada T, Sigl V, Schramek D, Penninger JM,. RANKL/RANK-beyond bones. J Mol Med (Berl). 2011; 89 (7): 647-56.
11. Lo Iacono N, Pangrazio A, Abinun M, et al. RANKL cytokine: from pioneer of the osteoimmunology era to cure for a rare disease. Clin Dev Immunol. 2013; 2013: 412768.
12. Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998; 12 (9): 1260-8.
13. Eghbali-Fatourechi G, Khosla S, Sanyal A, et al. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest. 2003; 111 (8): 1221-30.
14. Li X, Ominsky MS, Stolina M, et al. Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin. Bone. 2009; 45 (4): 669-76.
15. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009; 361 (8): 756-65.
16. Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009; 361 (8): 745-55.
17. Kostenuik PJ, Smith SY, Jolette J, Schroeder J, Pyrah I, Ominsky MS,. Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody. Bone. 2011; 49 (2): 151-61.
18. Kostenuik PJ, Nguyen HQ, McCabe J, et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res. 2009; 24 (2): 182-95.
19. Mizuno A, Kanno T, Hoshi M, et al. Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis. J Bone Miner Metab. 2002; 20 (6): 337-44.
20. Douni E, Rinotas V, Makrinou E, et al. A RANKL G278R mutation causing osteopetrosis identifies a functional amino acid essential for trimer assembly in RANKL and TNF. Hum Mol Genet. 2012; 21 (4): 784-98.
21. Douni E, Alexiou M, Kollias G,. Genetic engineering in the mouse: tuning TNF/TNFR expression. Methods Mol Med. 2004; 98: 137-70.
22. Dacquin R, Davey RA, Laplace C, et al. Amylin inhibits bone resorption while the calcitonin receptor controls bone formation in vivo. J Cell Biol. 2004; 164 (4): 509-14.
23. Mugniery E, Dacquin R, Marty C, et al. An activating Fgfr3 mutation affects trabecular bone formation via a paracrine mechanism during growth. Hum Mol Genet. 2012; 21 (11): 2503-13.
24. Bouxsein ML, Myers KS, Shultz KL, Donahue LR, Rosen CJ, Beamer WG,. Ovariectomy-induced bone loss varies among inbred strains of mice. J Bone Miner Res. 2005; 20 (7): 1085-92.
25. O'Brien CA, Nakashima T, Takayanagi H,. Osteocyte control of osteoclastogenesis. Bone. 2013; 54 (2): 258-63.
26. Van Keuren ML, Gavrilina GB, Filipiak WE, Zeidler MG, Saunders TL,. Generating transgenic mice from bacterial artificial chromosomes: transgenesis efficiency, integration and expression outcomes. Transgenic Res. 2009; 18 (5): 769-85.
27. Cooper DM, Thomas CD, Clement JG, Turinsky AL, Sensen CW, Hallgrimsson B,. Age-dependent change in the 3D structure of cortical porosity at the human femoral midshaft. Bone. 2007; 40 (4): 957-65.
28. Rosen CJ, Klibanski A,. Bone, fat, and body composition: evolving concepts in the pathogenesis of osteoporosis. Am J Med. 2009; 122 (5): 409-14.
29. Li X, Kuo D, Schafer AL, et al. Quantification of vertebral bone marrow fat content using 3 Tesla MR spectroscopy: reproducibility, vertebral variation, and applications in osteoporosis. J Magn Reson Imaging. 2011; 33 (4): 974-9.
30. Rosen CJ, Bouxsein ML,. Mechanisms of disease: is osteoporosis the obesity of bone ? Nat Clin Pract Rheumatol. 2006; 2 (1): 35-43.
31. Foo C, Frey S, Yang HH, Zellweger R, Filgueira L,. Downregulation of beta-catenin and transdifferentiation of human osteoblasts to adipocytes under estrogen deficiency. Gynecol Endocrinol. 2007; 23 (9): 535-40.
32. Kaden JJ, Bickelhaupt S, Grobholz R, et al. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification. J Mol Cell Cardiol. 2004; 36 (1): 57-66.
33. Tseng W, Graham LS, Geng Y, et al. PKA-induced receptor activator of NF-kappaB ligand (RANKL) expression in vascular cells mediates osteoclastogenesis but not matrix calcification. J Biol Chem. 2010; 285 (39): 29925-31.
34. Helas S, Goettsch C, Schoppet M, et al. Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice. Am J Pathol. 2009; 175 (2): 473-8.
35. Lo Iacono N, Blair HC, Poliani PL, et al. Osteopetrosis rescue upon RANKL administration to Rankl(-/-) mice: a new therapy for human RANKL-dependent ARO. J Bone Miner Res. 2012; 27 (12): 2501-10.
36. Kim N, Odgren PR, Kim DK, Marks SC Jr, Choi Y,. Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene. Proc Natl Acad Sci USA. 2000; 97 (20): 10905-10.
37. Ominsky MS, Stouch B, Schroeder J, et al. Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys. Bone. 2011; 49 (2): 162-73.